Patients for Affordable Drugs (P4AD) in a new report targeting GlaxoSmithKline (GSK) claims the drugmaker has displayed a "pattern of ... abusing the system in order to maintain monopolies on their products and keep prices high for patients." The organization in its report claims the drugmaker has, […]
New Syndicated Report – Orphan Drug Launch Strategies: Case Studies
Compared to mainstream drug launches, it's usually a much smaller team with fewer resources that are tasked with bringing a new orphan drug to market. And the market itself is smaller too – fewer specialists to talk to, fewer physicians to educate, and fewer patients to engage with. But smaller […]
Are the Days of Unfettered Pharmaceutical Pricing Gone?
Jack Bailey, President of GlaxoSmithKline Plc's U.S. Pharmaceuticals, is working on bringing new drugs to market as efficiently as possible and says the days of unfettered pricing are done. Read more here. (Source: Cynthia Koons, Bloomberg Business, 2/11/16) […]
Will Performance Pricing Ever Catch on with Payers?
Novaris CEO, Joe Jimenez recently discussed Big Data and performance-based pricing in an interview with the Swiss daily, Le Temps. Read more here. (Source: Tracy Staton, FiercePharma, 9/8/15) […]
Another Failed Product – What Will GSK Do Now?
With GlaxoSmithKline's megablockbuster Advair soon to be experiencing fierce generic competition, investors were assured that the pharma giant had another remedy in hand. Excitement built around Breo Ellipta, a drug developed to improve the mortality rate of high-risk patients with COPD, but the […]
Is the Current Pharmaceutical Pricing Model Coming to an End in the U.S.?
Dramatic changes in bringing drugs to market are forcing pharmaceutical companies to look at new strategies for survival. Are the times of super-high prices coming to an end? See more here. (Source: David Sell, philly.com, 8/11/15) […]
Which Drugs Made it on Express Scripts’ 2016 Formulary?
Express Scripts, the largest U.S. pharmacy benefits manager, has released its 2016 formulary outlining which drugs will be covered, and which will not. Who made the cut, and how did they decide? Find out here. (Source: Nicole Gray, BioPharmaDive, 8/6/15) […]
Drugmakers to Start Using Apple’s ResearchKit in Clinical Trails
GlaxoSmithKline (GSK) and Purdue Pharma are reportedly looking to integrate Apple's ResearchKit in clinical trials. Learn more about how ResearchKit is being used, here. (Source: Katie Bell, FirstWord Pharma, 7/13/15) […]
Will GSK Meningitis Vaccine Negotiations Be Successful In The UK?
GlaxoSmithKline continues negotiations in the UK to get approval for its meningitis B vaccine, Bexsero. How low will the agreed price be? See more here. (Source: Anna Bratulic, FirstWord Pharma, 3/22/15) […]
Could Ebola Vaccines Be Released Without Clinical Trials?
Health authorities are determined to get Ebola vaccines deployed and in use within months, dispensing with some of the usual testing, but raising unprecedented ethical and practical questions. The World Health Organization (WHO) has convened vaccine specialists, epidemiologists, pharmaceutical […]
